1. Epigenetics
    Cell Cycle/DNA Damage
    Autophagy
  2. PARP
    Autophagy

Veliparib dihydrochloride (Synonyms: ABT-888 dihydrochloride)

Cat. No.: HY-10130 Purity: 99.79%
Data Sheet SDS Handling Instructions

Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively.

For research use only. We do not sell to patients.
Veliparib dihydrochloride Chemical Structure

Veliparib dihydrochloride Chemical Structure

CAS No. : 912445-05-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $70 In-stock
50 mg $200 In-stock
100 mg $320 In-stock
200 mg $520 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Veliparib dihydrochloride:

    Veliparib dihydrochloride purchased from MCE. Usage Cited in: Electrostatics Joint Conference. 2016 July.

    Dose curve of Veliparib on MDA-MB-231 cells without Electroporation.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively.

    IC50 & Target

    Ki: 5.2 nM (PARP1), 2.9 nM (PARP2)

    In Vitro

    Veliparib is inactive to SIRT2 (>5 μM)[1]. Veliparib inhibits the PARP activity with EC50 of 2 nM in C41 cells[2]. Veliparib can decrease the PAR levels in both irradiated and nonirradiated H460 cells. Veliparib reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. Veliparib increases apoptosis and autophagy in H460 cells when combination with radiation[3]. Veliparib inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. Veliparib (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. Veliparib shows effective radiosensitivity in oxic H1299 cells. Veliparib can attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1[4].

    In Vivo

    The oral bioavailability of Veliparib is 56%-92% in mice, SD rats, beagle dogs, and cynomolgus monkeys after oral administration[1]. Veliparib (25 mg/kg, i.p.) can improve tumor growth delay in a NCI-H460 xenograft model. Combination with radiation, veliparib decreases the tumor vessel formation[3]. Veliparib reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression can be maintained over time[4]

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT01489865 Georgetown University|Abbott Metastatic Pancreatic Cancer February 2011 Phase 1|Phase 2
    NCT01009788 Steven Isakoff, MD, PhD|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Abbott|Massachusetts General Hospital Breast Cancer|Metastatic Breast Cancer|BRCA1 Gene Mutation|brca2 Gene Mutation November 2009 Phase 2
    NCT01495351 Alberta Health Services|Tom Baker Cancer Centre|Abbott|AHS Cancer Control Alberta Multiple Myeloma January 2012 Phase 1
    NCT01205828 Georgetown University|Abbott Hepatocellular Carcinoma August 2010 Phase 2
    NCT01051596 Georgetown University|Abbott Colorectal Cancer September 2009 Phase 2
    NCT00649207 AbbVie (prior sponsor, Abbott)|AbbVie Brain Diseases|Brain Neoplasms|Central Nervous System Diseases|Neoplasm Metastasis|Nervous System Neoplasms March 2008 Phase 1
    NCT01113957 AbbVie (prior sponsor, Abbott)|AbbVie Ovarian Cancer March 2010 Phase 2
    NCT01085422 AbbVie (prior sponsor, Abbott)|Prostate Cancer Clinical Trials Consortium|AbbVie Prostate Cancer April 2010 Phase 1
    NCT00804908 AbbVie (prior sponsor, Abbott)|AbbVie Melanoma|Metastatic Melanoma|Skin Cancer February 2009 Phase 2
    NCT01445522 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms|Lymphoma December 3, 2008 Phase 1
    NCT02210663 AbbVie Advanced Solid Tumors July 2014 Phase 1
    NCT01306032 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Ovarian Cancer|Primary Peritoneal Cancer|Serous Carcinoma Cancer|Triple-Negative Breast Cancer|Fallopian Tube Cancer January 12, 2011 Phase 2
    NCT00994071 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Medulloblastoma|Pontine Glioma|Ependymoma|Astrocytoma|PNET September 22, 2009 Phase 1
    NCT00553189 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Solid Tumors|Lymphomas August 9, 2007 Phase 1
    NCT00526617 Abbott Non-hematologic Malignancies|Metastatic Melanoma|Breast Cancer|Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Hepatocellular Carcinoma August 2007 Phase 1
    NCT01419548 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms July 29, 2011 Phase 1
    NCT02009631 AbbVie Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors November 2013 Phase 1
    NCT01617928 AbbVie (prior sponsor, Abbott)|AbbVie Solid Tumors May 2012 Phase 1
    NCT01063816 AbbVie (prior sponsor, Abbott)|AbbVie Advanced Solid Tumors January 2010 Phase 1
    NCT01026493 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology Brain and Central Nervous System Tumors July 2010 Phase 1|Phase 2
    NCT01042379 QuantumLeap Healthcare Collaborative Breast Neoplasms|Breast Cancer|Breast Tumors March 2010 Phase 2
    NCT01489865 Georgetown University|Abbott Metastatic Pancreatic Cancer February 2011 Phase 1|Phase 2
    NCT01009788 Steven Isakoff, MD, PhD|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Abbott|Massachusetts General Hospital Breast Cancer|Metastatic Breast Cancer|BRCA1 Gene Mutation|brca2 Gene Mutation November 2009 Phase 2
    NCT01495351 Alberta Health Services|Tom Baker Cancer Centre|Abbott|AHS Cancer Control Alberta Multiple Myeloma January 2012 Phase 1
    NCT01205828 Georgetown University|Abbott Hepatocellular Carcinoma August 2010 Phase 2
    NCT01051596 Georgetown University|Abbott Colorectal Cancer September 2009 Phase 2
    NCT00649207 AbbVie (prior sponsor, Abbott)|AbbVie Brain Diseases|Brain Neoplasms|Central Nervous System Diseases|Neoplasm Metastasis|Nervous System Neoplasms March 2008 Phase 1
    NCT01113957 AbbVie (prior sponsor, Abbott)|AbbVie Ovarian Cancer March 2010 Phase 2
    NCT01085422 AbbVie (prior sponsor, Abbott)|Prostate Cancer Clinical Trials Consortium|AbbVie Prostate Cancer April 2010 Phase 1
    NCT00804908 AbbVie (prior sponsor, Abbott)|AbbVie Melanoma|Metastatic Melanoma|Skin Cancer February 2009 Phase 2
    NCT01445522 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms|Lymphoma December 3, 2008 Phase 1
    NCT02210663 AbbVie Advanced Solid Tumors July 2014 Phase 1
    NCT01306032 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Ovarian Cancer|Primary Peritoneal Cancer|Serous Carcinoma Cancer|Triple-Negative Breast Cancer|Fallopian Tube Cancer January 12, 2011 Phase 2
    NCT00994071 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Medulloblastoma|Pontine Glioma|Ependymoma|Astrocytoma|PNET September 22, 2009 Phase 1
    NCT00553189 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Solid Tumors|Lymphomas August 9, 2007 Phase 1
    NCT00526617 Abbott Non-hematologic Malignancies|Metastatic Melanoma|Breast Cancer|Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Hepatocellular Carcinoma August 2007 Phase 1
    NCT01419548 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms July 29, 2011 Phase 1
    NCT02009631 AbbVie Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors November 2013 Phase 1
    NCT01617928 AbbVie (prior sponsor, Abbott)|AbbVie Solid Tumors May 2012 Phase 1
    NCT01063816 AbbVie (prior sponsor, Abbott)|AbbVie Advanced Solid Tumors January 2010 Phase 1
    NCT01026493 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology Brain and Central Nervous System Tumors July 2010 Phase 1|Phase 2
    NCT01042379 QuantumLeap Healthcare Collaborative Breast Neoplasms|Breast Cancer|Breast Tumors March 2010 Phase 2
    NCT02158507 University of Alabama at Birmingham|Scariot Foundation|GlaxoSmithKline|AbbVie Metastatic Triple Negative Breast Cancer July 2014
    NCT02289690 AbbVie Small Cell Lung Cancer October 2014 Phase 2
    NCT01853306 AbbVie Oncology|BRCA Mutated|High Grade Serous Ovarian Cancer|BRCA Mutated Breast Cancer March 18, 2013 Phase 1
    NCT01123876 AbbVie (prior sponsor, Abbott)|AbbVie Gastric Cancer March 2010 Phase 1
    NCT01690598 Vejle Hospital|Abbott Ovarian Cancer November 2012 Phase 1|Phase 2
    NCT01199224 Abbott Solid Tumors June 2010 Phase 1
    NCT02723864 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms March 22, 2016 Phase 1
    NCT00892736 National Cancer Institute (NCI) Basal-Like Breast Carcinoma|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Hereditary Breast and Ovarian Cancer Syndrome|Ovarian Carcinoma|Pancreatic Carcinoma|Progesterone Receptor Negative|Prostate Carcinoma|Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Solid Neoplasm|Triple-Negative Breast Carcinoma April 2009 Phase 1
    NCT01351909 National Cancer Institute (NCI) HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer May 2, 2011 Phase 1
    NCT01540565 National Cancer Institute (NCI) BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ovarian Epithelial Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma April 9, 2012 Phase 2
    NCT01193140 Abbott Solid Tumor Cancers July 2010 Phase 2
    NCT03123211 AbbVie Cancer
    NCT01434316 National Cancer Institute (NCI) Advanced Malignant Solid Neoplasm|BRCA1 Gene Mutation|BRCA2 Gene Mutation November 1, 2011 Phase 1
    NCT01908478 Cedars-Sinai Medical Center|AbbVie Pancreatic Cancer July 2013 Phase 1
    NCT01589419 AbbVie (prior sponsor, Abbott)|AbbVie Locally Advanced Rectal Cancer June 2012 Phase 1
    NCT02860819 National Cancer Institute, Slovakia Testicular Cancer July 2016 Phase 2
    NCT01472783 Vejle Hospital|Abbott Recurrent, Epithelial Ovarian Cancer November 2011 Phase 1|Phase 2
    NCT00588991 National Cancer Institute (NCI) Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Adult Acute Myeloid Leukem November 28, 2007 Phase 1
    NCT01139970 National Cancer Institute (NCI) Accelerated Phase of Disease|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Adult Acute Promyelocytic Leukemia With PML-RARA|Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9; May 21, 2010 Phase 1
    NCT02412371 AbbVie Non-small Cell Lung Cancer Stage III April 30, 2015 Phase 2
    NCT01282333 National Cancer Institute (NCI) Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Stage III Bladder Cancer|Stage III Pancreatic Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Bladder Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Transitional Cell Carcinoma of the Bladder|Unresectable Extrahepat January 2011 Phase 1
    NCT01233505 National Cancer Institute (NCI) Adenocarcinoma of the Pancreas|Adenocarcinoma of the Stomach|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ovarian Mucinous Cystadenocarcinoma|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Gastric Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Can October 2010 Phase 1
    NCT01145430 National Cancer Institute (NCI) Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma June 2010 Phase 1
    NCT02483104 AbbVie Ovarian Cancer July 2015 Phase 1
    NCT03032614 The University of Texas Health Science Center at San Antonio Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation July 31, 2017 Phase 2
    NCT01017640 National Cancer Institute (NCI) Solid Neoplasm October 2009 Phase 1
    NCT01104259 University of Washington|National Cancer Institute (NCI) Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Hereditary Breast/Ovarian Cancer - BRCA1|Hereditary Breast/Ovarian Cancer - BRCA2|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer July 16, 2010 Phase 1
    NCT01264432 National Cancer Institute (NCI) Adult Solid Neoplasm|Peritoneal Carcinomatosis|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma January 1, 2011 Phase 1
    NCT01477489 University of Michigan Cancer Center Breast Cancer January 2012 Phase 1
    NCT01366144 National Cancer Institute (NCI)|Abbott Breast Carcinoma|Carcinoma of Unknown Primary Origin|Endometrial Carcinoma|Esophageal Carcinoma|Lung Carcinoma|Malignant Head and Neck Neoplasm|Melanoma|Ovarian Carcinoma|Renal Pelvis and Ureter Urothelial Carcinoma|Testicular Lymphoma June 20, 2011 Phase 1
    NCT01326702 National Cancer Institute (NCI) Adult B Acute Lymphoblastic Leukemia|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Adult Solid Neoplasm|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Cutaneous B-Cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Recurr July 2011 Phase 1|Phase 2
    NCT02944396 AbbVie Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) December 28, 2016 Phase 2
    NCT01149083 National Cancer Institute (NCI) BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer June 30, 2010 Phase 2
    NCT02631733 National Cancer Institute (NCI) Malignant Solid Neoplasm July 15, 2016 Phase 1
    NCT01560104 AbbVie (prior sponsor, Abbott)|AbbVie Non-Small -Cell Lung Cancer February 2012 Phase 2
    NCT02106546 AbbVie Squamous Non-Small Cell Lung Cancer April 2014 Phase 3
    NCT02849496 National Cancer Institute (NCI) BRCA1 Gene Mutation|BRCA2 Gene Mutation|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma November 15, 2016 Phase 2
    NCT01585805 National Cancer Institute (NCI) BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Metastatic Pancreatic Adenocarcinoma|PALB2 Gene Mutation|Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7 April 18, 2012 Phase 2
    NCT03044795 University Medical Center Groningen|AbbVie|Dutch Cancer Society Cancer August 2017 Phase 2
    NCT01514201 National Cancer Institute (NCI) Childhood Mixed Glioma|Untreated Childhood Anaplastic Astrocytoma|Untreated Childhood Brain Stem Glioma|Untreated Childhood Fibrillary Astrocytoma|Untreated Childhood Giant Cell Glioblastoma|Untreated Childhood Glioblastoma|Untreated Childhood Gliosarcoma November 17, 2011 Phase 1|Phase 2
    NCT02163694 AbbVie Metastatic Breast Cancer July 2014 Phase 3
    NCT03061188 Northwestern University|Bristol-Myers Squibb|AbbVie|National Cancer Institute (NCI) Advanced Solid Neoplasm|Aggressive Non-Hodgkin Lymphoma|Recurrent Solid Neoplasm|Refractory Mantle Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma|Unresectable Solid Neoplasm May 23, 2017 Phase 1
    NCT01012817 National Cancer Institute (NCI) Metastatic Malignant Solid Neoplasm|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Unresectable Solid Neoplasm October 29, 2009 Phase 1|Phase 2
    NCT01281150 National Cancer Institute (NCI) Adult Solid Neoplasm|Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma January 2011 Phase 1
    NCT01749397 National Cancer Institute (NCI) Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer December 7, 2012 Phase 1
    NCT02305758 AbbVie Untreated Metastatic Colorectal Cancer December 11, 2014 Phase 2
    NCT02033551 AbbVie Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors December 2013 Phase 1
    NCT01386385 National Cancer Institute (NCI) Large Cell Lung Carcinoma|Lung Adenocarcinoma|Lung Adenocarcinoma, Mixed Subtype|Minimally Invasive Lung Adenocarcinoma|Squamous Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7 June 20, 2011 Phase 1|Phase 2
    NCT01154426 National Cancer Institute (NCI) Adult Solid Neoplasm|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier May 2010 Phase 1
    NCT01281852 National Cancer Institute (NCI) Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer March 2011 Phase 1|Phase 2
    NCT02595905 National Cancer Institute (NCI) BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Breast Carcinoma Metastatic in the Brain|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma July 7, 2016 Phase 2
    NCT02264990 AbbVie Non-squamous Non-small Cell Lung Cancer September 30, 2014 Phase 3
    NCT01506609 AbbVie (prior sponsor, Abbott)|AbbVie Metastatic Breast Cancer January 24, 2012 Phase 2
    NCT01657799 AbbVie (prior sponsor, Abbott)|AbbVie Brain Metastases From Non-small Cell Lung Cancer October 2012 Phase 2
    NCT00576654 National Cancer Institute (NCI) Advanced Malignant Solid Neoplasm|Breast Carcinoma|Colon Carcinoma|Deleterious BRCA1 Gene Mutation|Estrogen Receptor Negative|HER2/Neu Negative|Hodgkin Lymphoma|Lung Carcinoma|Metastatic Malignant Neoplasm|Metastatic Malignant Solid Neoplasm|Non-Hodgkin Lymphoma|Ovarian Carcinoma|Pancreatic Carcinoma|Progesterone Receptor Negative|Stage III Breast Cancer|Stage III Colon Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Ovarian Cancer|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Bre December 5, 2007 Phase 1
    NCT01251874 National Cancer Institute (NCI) BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma November 16, 2010 Phase 1
    NCT01642251 National Cancer Institute (NCI) Extensive Stage Small Cell Lung Carcinoma|Large Cell Lung Carcinoma|Neuroendocrine Carcinoma|Small Cell Carcinoma|Stage IV Non-Small Cell Lung Cancer AJCC v7 September 28, 2012 Phase 1|Phase 2
    NCT03227016 Central European Society for Anticancer Drug Research Small Cell Lung Cancer SCLC October 2016 Phase 1
    NCT00740805 National Cancer Institute (NCI) Solid Neoplasm|Stage III Non-Hodgkin Lymphoma|Stage IV Non-Hodgkin Lymphoma August 18, 2008 Phase 1
    NCT01711541 National Cancer Institute (NCI) Head and Neck Squamous Cell Carcinoma|Stage IVA Oropharyngeal Carcinoma AJCC v7|Stage IVB Oropharyngeal Carcinoma AJCC v7 October 22, 2012 Phase 1|Phase 2
    NCT02985658 University of Washington|AbbVie Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation|Triple-Negative Breast Cancer
    NCT01459380 National Cancer Institute (NCI) Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma October 11, 2011 Phase 1
    NCT02152982 National Cancer Institute (NCI) Glioblastoma|Gliosarcoma December 15, 2014 Phase 2|Phase 3
    NCT01576172 National Cancer Institute (NCI) Hormone-Resistant Prostate Cancer|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer May 21, 2012 Phase 2
    NCT01638546 National Cancer Institute (NCI) Recurrent Small Cell Lung Carcinoma June 2012 Phase 2
    NCT02831179 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Functional Pancreatic Neuroendocrine Tumor|Malignant Somatostatinoma|Merkel Cell Carcinoma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Carcinoid Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Neuroendocrine Neoplasm|Non-Functional Pancreatic Neuroendocrine Tumor|Pancreatic Glucagonoma|Pancreatic Insulinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Merkel Cell Carcinoma|Somato December 2017 Phase 1
    NCT01266447 National Cancer Institute (NCI) Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage III Cervical Cancer|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer February 2011 Phase 2
    NCT00946335 National Cancer Institute (NCI) Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelio July 2009 Phase 1
    NCT01818063 Sidney Kimmel Cancer Center at Thomas Jefferson University|Susan G. Komen Breast Cancer Foundation|Thomas Jefferson University Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer April 25, 2013 Phase 2
    NCT02890355 National Cancer Institute (NCI) Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage IV Pancreatic Cancer AJCC v6 and v7 September 1, 2016 Phase 2
    NCT00535119 National Cancer Institute (NCI) Adult Solid Neoplasm|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Hereditary Breast and Ovarian Cancer Syndrome September 2007 Phase 1
    NCT02470585 AbbVie|Gynecologic Oncology Group|Australia New Zealand Gynaecological Oncology Group Ovarian Cancer|Ovarian Neoplasm July 14, 2015 Phase 3
    NCT00387608 National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Leukemia|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific June 2006 Phase 1
    NCT00989651 National Cancer Institute (NCI) Fallopian Tube Carcinosarcoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Neoplasm|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Carcinosarcoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Tumor|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Primary Peritoneal Serous Adenoca October 28, 2009 Phase 1
    NCT00770471 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Brain and Central Nervous System Tumors June 2009 Phase 1|Phase 2
    NCT02032277 AbbVie|US Oncology Research|NSABP Foundation Inc|Alliance for Clinical Trials in Oncology|German Breast Group|Grupo Español de Investigación del Cáncer de Mama Triple Negative Breast Cancer April 2, 2014 Phase 3
    NCT02921256 National Cancer Institute (NCI) Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v7|Stage III Rectal Cancer AJCC v7 October 12, 2016 Phase 2
    NCT01827384 National Cancer Institute (NCI) Advanced Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm December 31, 2013 Phase 2
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 3.1525 mL 15.7624 mL 31.5249 mL
    5 mM 0.6305 mL 3.1525 mL 6.3050 mL
    10 mM 0.3152 mL 1.5762 mL 3.1525 mL
    Kinase Assay
    [1]

    PARP assays are conducted in a buffer containing 50 mM Tris (pH 8.0), 1 mM DTT, 1.5 μM [3H]NAD+ (1.6 μCi/mmol), 200 nM biotinylated histone H1, 200 nM slDNA, and 1 nM PARP-1 or 4 nM PARP-2 enzyme. Reactions are terminated with 1.5 mM benzamide, transferred to streptavidin Flash plates, and counted using a TopCount microplate scintillation counter. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Veliparib is formulated in 0.9% NaCl.

    For B16F10 syngeneic studies, 6×104 cells are mixed with 50% Matrigel and inoculated by s.c. injection into the flank of 6- to 8-week-old female C57BL/6 mice (20 g). For cisplatin efficacy studies, female nude mice are implanted s.c. by trocar with fragments (20-30 mm3) of human tumors harvested from s.c. grown tumors in nude mice hosts. For the carboplatin and MX-1 cyclophosphamide studies, female scid mice are inoculated with 200 μL of a 1:10 dilution of tumor brei in 45% Matrigel and 45% Spinner MEM. For these established tumor studies, tumors are allowed to grow to the indicated size and then randomized to therapy groups. For DOHH-2 xenograft studies, 1×106 cells are mixed with 50% Matrigel and inoculated by s.c. injection into the flank of male scid mice. Veliparib is delivered by either oral route or continuous infusion using s.c. placement of 14-day Alzet OMP model 2002 in a vehicle containing 0.9% NaCl adjusted to pH 4.0. The OMP delivers at a rate of 12 μL daily and Veliparib doses are calculated accordingly. Temozolomide, cisplatin, carboplatin, and cyclophosphamide are formulated according to the manufacturers' recommendations. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    317.21

    Formula

    C₁₃H₁₈Cl₂N₄O

    CAS No.

    912445-05-7

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 3.2 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Veliparib dihydrochloride
    Cat. No.:
    HY-10130
    Quantity: